{
    "protocolSection": {
        "identificationModule": {
            "nctId": "NCT06346067",
            "orgStudyIdInfo": {
                "id": "ERAS-254-02"
            },
            "organization": {
                "fullName": "Erasca, Inc.",
                "class": "INDUSTRY"
            },
            "briefTitle": "A Study to Assess Naporafenib (ERAS-254) Administered With Trametinib in Patients With NRAS-mutant Melanoma (SEACRAFT-2)",
            "officialTitle": "A Randomized, Open-label Phase III Study in Patients With Previously Treated Unresectable or Metastatic NRAS Mutant Cutaneous Melanoma Comparing the Combination of Naporafenib + Trametinib to Physician's Choice of Therapy (Dacarbazine, Temozolomide or Trametinib Monotherapy) With a Dose Optimization lead-in [SEACRAFT-2]",
            "therapeuticArea": [
                "Oncology and Hematology"
            ],
            "study": "a-study-to-assess-naporafenib-eras-administered-with-trametinib-in-patients-with-nras-mutant-melanoma-seacraft"
        },
        "statusModule": {
            "statusVerifiedDate": "2024-07",
            "overallStatus": "RECRUITING",
            "expandedAccessInfo": {
                "hasExpandedAccess": false
            },
            "startDateStruct": {
                "date": "2024-04-29",
                "type": "ACTUAL"
            },
            "primaryCompletionDateStruct": {
                "date": "2028-04",
                "type": "ESTIMATED"
            },
            "completionDateStruct": {
                "date": "2028-12",
                "type": "ESTIMATED"
            },
            "studyFirstSubmitDate": "2024-03-17",
            "studyFirstSubmitQcDate": "2024-03-28",
            "studyFirstPostDateStruct": {
                "date": "2024-04-03",
                "type": "ACTUAL"
            },
            "lastUpdateSubmitDate": "2024-07-22",
            "lastUpdatePostDateStruct": {
                "date": "2024-07-23",
                "type": "ACTUAL"
            }
        },
        "sponsorCollaboratorsModule": {
            "responsibleParty": {
                "type": "SPONSOR"
            },
            "leadSponsor": {
                "name": "Erasca, Inc.",
                "class": "INDUSTRY"
            }
        },
        "oversightModule": {
            "oversightHasDmc": true,
            "isFdaRegulatedDrug": true,
            "isFdaRegulatedDevice": false
        },
        "descriptionModule": {
            "briefSummary": "Stage 1: To select the optimal dose of naporafenib + trametinib to be studied in Stage 2.\n\nStage 2: To compare progression free survival (PFS) and overall survival (OS) for patients with NRAS-mutant (NRASm) melanoma who are randomized to receive the combination of naporafenib + trametinib to that of patients who are randomized to physician's choice of therapy (dacarbazine, temozolomide, or trametinib monotherapy).",
            "detailedDescription": "SEACRAFT-2 is a global, Phase III, open-label, randomized study to assess the efficacy and safety of naporafenib administered with trametinib compared to physician's choice of therapy (dacarbazine, temozolomide, or trametinib monotherapy) in patients with unresectable or metastatic NRAS mutant melanoma who have progressed on, or are intolerant to, an anti-programmed death-1 ligand 1 (PD 1/L1)-based regimen. The study will consist of 2 stages: dose optimization in Stage 1 and the Phase 3 portion in Stage 2.\n\nA total of approximately 470 eligible patients will be randomized to receive study drug(s) in this study across 2 stages."
        },
        "conditionsModule": {
            "conditions": [
                "Advanced or Metastatic NRAS-mutant Melanoma"
            ],
            "keywords": [
                "Melanoma",
                "NRAS Mutant",
                "Cutaneous Melanoma"
            ]
        },
        "designModule": {
            "studyType": "INTERVENTIONAL",
            "phases": [
                "PHASE3"
            ],
            "designInfo": {
                "allocation": "RANDOMIZED",
                "interventionModel": "PARALLEL",
                "primaryPurpose": "TREATMENT",
                "maskingInfo": {
                    "masking": "NONE"
                }
            },
            "enrollmentInfo": {
                "count": 470,
                "type": "ESTIMATED"
            }
        },
        "armsInterventionsModule": {
            "armGroups": [
                {
                    "label": "Stage 1 Dose selection Lead-in Arm 1",
                    "type": "EXPERIMENTAL",
                    "description": "Naporafenib + Trametinib Naporafenib (ERAS-254) 100 mg administered orally twice daily (BID) Trametinib 1 mg once daily (QD)",
                    "interventionNames": [
                        "Drug: Naporafenib",
                        "Drug: Trametinib"
                    ]
                },
                {
                    "label": "Stage 1 Dose selection Lead-in Arm 2",
                    "type": "EXPERIMENTAL",
                    "description": "Naporafenib + Trametinib Naporafenib (ERAS-254) 400 mg administered orally twice daily (BID) Trametinib 0.5 mg once daily (QD)",
                    "interventionNames": [
                        "Drug: Naporafenib",
                        "Drug: Trametinib"
                    ]
                },
                {
                    "label": "Stage 1 Dose selection Lead-in Arm 3 Trametinib monotherapy",
                    "type": "ACTIVE_COMPARATOR",
                    "description": "Trametinib 2 mg once daily (QD)",
                    "interventionNames": [
                        "Drug: Trametinib"
                    ]
                },
                {
                    "label": "Stage 2 Arm A",
                    "type": "EXPERIMENTAL",
                    "description": "Naporafenib + Trametinib Naporafenib (ERAS-254) BID oral administration with Trametinib QD at the dose selected in Stage 1",
                    "interventionNames": [
                        "Drug: Naporafenib",
                        "Drug: Trametinib"
                    ]
                },
                {
                    "label": "Stage 2 Arm B - Physician's Choice",
                    "type": "ACTIVE_COMPARATOR",
                    "description": "* Dacarbazine 1000 mg/m2 intravenously (IV) on Day 1 of each 21-day cycle OR\n* Temozolomide 200 mg/m2/day PO on Day 1 to Day 5 of each 28-day cycle OR\n* Trametinib monotherapy, 2 mg PO QD",
                    "interventionNames": [
                        "Drug: Dacarbazine",
                        "Drug: Temozolomide",
                        "Drug: Trametinib"
                    ]
                }
            ],
            "interventions": [
                {
                    "type": "DRUG",
                    "name": "Naporafenib",
                    "description": "Naporafenib (ERAS-254) is an experimental Pan-Raf inhibitor",
                    "armGroupLabels": [
                        "Stage 1 Dose selection Lead-in Arm 1",
                        "Stage 1 Dose selection Lead-in Arm 2",
                        "Stage 2 Arm A"
                    ],
                    "otherNames": [
                        "ERAS-254",
                        "LXH254"
                    ]
                },
                {
                    "type": "DRUG",
                    "name": "Dacarbazine",
                    "description": "Dacarbazine IV - Day 1",
                    "armGroupLabels": [
                        "Stage 2 Arm B - Physician's Choice"
                    ],
                    "otherNames": [
                        "DTIC"
                    ]
                },
                {
                    "type": "DRUG",
                    "name": "Temozolomide",
                    "description": "Temozolomide 200 mg/m2/day PO on Day 1 to Day 5 of each 28-day cycle",
                    "armGroupLabels": [
                        "Stage 2 Arm B - Physician's Choice"
                    ],
                    "otherNames": [
                        "Temodar",
                        "TMZ"
                    ]
                },
                {
                    "type": "DRUG",
                    "name": "Trametinib",
                    "description": "Trametinib is an FDA approved anticancer medication that targets MEK1 and MEK2.",
                    "armGroupLabels": [
                        "Stage 1 Dose selection Lead-in Arm 1",
                        "Stage 1 Dose selection Lead-in Arm 2",
                        "Stage 1 Dose selection Lead-in Arm 3 Trametinib monotherapy",
                        "Stage 2 Arm A",
                        "Stage 2 Arm B - Physician's Choice"
                    ],
                    "otherNames": [
                        "Mekinist"
                    ]
                }
            ]
        },
        "outcomesModule": {
            "primaryOutcomes": [
                {
                    "measure": "Stage 1:To select the optimal dose of naporafenib + trametinib to be studied in Stage 2",
                    "description": "Incidence and severity of treatment-emergent AEs and serious AEs",
                    "timeFrame": "Assessed up to 6 months from time of first dose"
                },
                {
                    "measure": "Stage 1:To select the optimal dose of naporafenib + trametinib to be studied in Stage 2",
                    "description": "Objective response rate (ORR) based on assessment of radiographic imaging RECIST v1.1",
                    "timeFrame": "Assessed up to 6 months from time of first dose"
                },
                {
                    "measure": "Stage 1:To select the optimal dose of naporafenib + trametinib to be studied in Stage 2",
                    "description": "Maximum plasma concentration of ERAS-254 and trametinib",
                    "timeFrame": "Study Day 1 up to Day 29"
                },
                {
                    "measure": "Stage 1:To select the optimal dose of naporafenib + trametinib to be studied in Stage 2",
                    "description": "Time to achieve maximum plasma concentration of ERAS-254 and trametinib",
                    "timeFrame": "Study Day 1 up to Day 29"
                },
                {
                    "measure": "Stage 1:To select the optimal dose of naporafenib + trametinib to be studied in Stage 2",
                    "description": "Area under the plasma concentration-time curve",
                    "timeFrame": "Study Day 1 up to Day 29"
                },
                {
                    "measure": "Stage 2: To compare PFS and OS for patients who are randomized to receive the combination of naporafenib + trametinib to that of patients who receive physician's choice of therapy (dacarbazine, temozolomide, or trametinib monotherapy)",
                    "description": "* Progression free survival (PFS) based on assessment of radiographic imaging per RECIST v1.1\n* Survival status",
                    "timeFrame": "Assessed up to 24 months from time of first dose"
                }
            ],
            "secondaryOutcomes": [
                {
                    "measure": "Adverse Events",
                    "description": "Incidence and severity of treatment-emergent AEs and serious AEs",
                    "timeFrame": "Assessed up to 24 months from time of first dose"
                },
                {
                    "measure": "Duration of Response (DOR)",
                    "description": "Based on assessment of radiographic imaging per RECIST version 1.1",
                    "timeFrame": "Assessed up to 24 months from time of first dose]"
                },
                {
                    "measure": "Time to Response (TTR)",
                    "description": "Based on assessment of radiographic imaging per RECIST version 1.1",
                    "timeFrame": "Assessed up to 24 months from time of first dose]"
                },
                {
                    "measure": "Disease Control Rate (DCR)",
                    "description": "Based on assessment of radiographic imaging per RECIST version 1.1",
                    "timeFrame": "Assessed up to 24 months from time of first dose]"
                },
                {
                    "measure": "Overall Response Rate (ORR)",
                    "description": "Based on the assessment of radiographic imaging per RECIST version 1.1",
                    "timeFrame": "Assessed up to 24 months from time of first dose"
                },
                {
                    "measure": "Plasma concentration (Cmax):Stage 1 only",
                    "description": "Maximum plasma concentration of ERAS-254 and trametinib",
                    "timeFrame": "Study Day 1 up to Day 29"
                },
                {
                    "measure": "Area under the curve (AUC):Stage 1 only",
                    "description": "Area under the plasma concentration-time curve",
                    "timeFrame": "Study Day 1 up to Day 29"
                },
                {
                    "measure": "Quality of Life: To assess disease and treatment-related QOL in patients with NRASm melanoma.",
                    "description": "Using the European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire \\[QLQ\\]-C30 subscales and PRO CTCAE\u00ae symptom items specific to the potential cutaneous toxicities.",
                    "timeFrame": "Assessed up to 24 months from time of first dose"
                }
            ],
            "otherOutcomes": [
                {
                    "measure": "Duration of Response (DOR) for CNS disease in participants",
                    "description": "Based on Response Assessment in Neuro-Oncology Brain Metastases (RANO-BM)",
                    "timeFrame": "Assessed up to 24 months from time of first dose"
                },
                {
                    "measure": "Overall Response Rate (ORR) for CNS disease in participants",
                    "description": "Based on Response Assessment in Neuro-Oncology Brain Metastases (RANO-BM)",
                    "timeFrame": "Assessed up to 24 months from time of first dose"
                },
                {
                    "measure": "Disease Control Rate (DCR) for CNS disease in participants",
                    "description": "Based on Response Assessment in Neuro-Oncology Brain Metastases (RANO-BM)",
                    "timeFrame": "Assessed up to 24 months from time of first dose"
                }
            ]
        },
        "eligibilityModule": {
            "eligibilityCriteria": "Key Inclusion Criteria:\n\n1. Willing and able to provide written informed consent\n2. Age \u2265 18 years\n3. Histologically or cytologically confirmed unresectable or metastatic cutaneous (includes acral) melanoma.\n4. Documentation of an NRAS mutation (tumor tissue or blood) prior to first dose of study drug(s) as determined locally with an analytically validated assay in a certified testing laboratory.\n5. Archival tumor tissue collected within 5 years prior to enrollment must be confirmed to be available at the time of Screening, which may be submitted before or after enrollment for exploratory biomarker analysis.\n6. Must have received an anti-PD-1/L1 based regimen (monotherapy or combination). Patient must have documented disease progression either while receiving therapy or within 12 weeks of last dose of the most recent anti-PD-1/L1 based regimen; the patient is eligible if they have received other therapies between the most recent anti-PD-1/L1 based regimen and enrollment.\n7. ECOG performance status 0, 1 or 2\n8. Presence of at least 1 measurable lesion according to RECIST v1.1\n9. Able to swallow oral medication.\n\nKey Exclusion Criteria:\n\n1. Patients with uveal or mucosal melanoma\n2. Prior therapy with an ERK-, MEK-, RAF-, or RAS-inhibitor\n3. Impairment of gastrointestinal (GI) function or GI disease that may significantly alter the absorption of study drug(s) (e.g., ulcerative diseases, uncontrolled nausea, vomiting, diarrhea, malabsorption syndrome, small bowel resection)\n4. History or current evidence of retinal vein occlusion (RVO) or current risk factors for RVO (e.g., uncontrolled glaucoma or ocular hypertension, history of hyperviscosity or hypercoagulability syndrome)\n5. LVEF \\<50%\n6. Symptomatic CNS metastases that are neurologically unstable. Patients with controlled CNS metastases are eligible.\n7. Patients receiving treatment with herbal medicine known to cause liver toxicity, which cannot be discontinued 7 days prior to first dose of study drug(s) and for the duration of the study.\n8. Are pregnant or breastfeeding or expecting to conceive or father children within the projected duration of the trial",
            "healthyVolunteers": false,
            "sex": "ALL",
            "minimumAge": "18 Years",
            "maximumAge": "99 Years",
            "stdAges": [
                "ADULT",
                "OLDER_ADULT"
            ]
        },
        "contactsLocationsModule": {
            "centralContacts": [
                {
                    "name": "Erasca Clinical Team",
                    "role": "CONTACT",
                    "phone": "1-858-465-6511",
                    "email": "clinicaltrials@erasca.com"
                }
            ],
            "overallOfficials": [
                {
                    "name": "Joyce Antal",
                    "affiliation": "Clinical Development",
                    "role": "STUDY_DIRECTOR"
                }
            ],
            "locations": [
                {
                    "facility": "The Melanoma and Skin Care Institute",
                    "status": "RECRUITING",
                    "city": "Englewood",
                    "state": "Colorado",
                    "zip": "80113",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 39.64777,
                        "lon": -104.98776
                    }
                },
                {
                    "facility": "Washington University School of Medicine",
                    "status": "RECRUITING",
                    "city": "Saint Louis",
                    "state": "Missouri",
                    "zip": "63110",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 38.62727,
                        "lon": -90.19789
                    }
                },
                {
                    "facility": "Cleveland Clinic Foundation",
                    "status": "RECRUITING",
                    "city": "Cleveland",
                    "state": "Ohio",
                    "zip": "44195",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 41.4995,
                        "lon": -81.69541
                    }
                },
                {
                    "facility": "SCRI Oncology Partners (formerly Tennessee Oncology)",
                    "status": "RECRUITING",
                    "city": "Nashville",
                    "state": "Tennessee",
                    "zip": "37203",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 36.16589,
                        "lon": -86.78444
                    }
                },
                {
                    "facility": "The University of Texas MD Anderson Cancer Center",
                    "status": "RECRUITING",
                    "city": "Houston",
                    "state": "Texas",
                    "zip": "77030",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 29.76328,
                        "lon": -95.36327
                    }
                },
                {
                    "facility": "Tasman Health Care",
                    "status": "RECRUITING",
                    "city": "Southport",
                    "state": "Queensland",
                    "zip": "4215",
                    "country": "Australia",
                    "geoPoint": {
                        "lat": -27.96724,
                        "lon": 153.39796
                    }
                }
            ]
        },
        "ipdSharingStatementModule": {
            "ipdSharing": "NO"
        }
    },
    "derivedSection": {
        "miscInfoModule": {
            "versionHolder": "2024-07-30"
        },
        "conditionBrowseModule": {
            "meshes": [
                {
                    "id": "D000008545",
                    "term": "Melanoma"
                }
            ],
            "ancestors": [
                {
                    "id": "D000018358",
                    "term": "Neuroendocrine Tumors"
                },
                {
                    "id": "D000017599",
                    "term": "Neuroectodermal Tumors"
                },
                {
                    "id": "D000009373",
                    "term": "Neoplasms, Germ Cell and Embryonal"
                },
                {
                    "id": "D000009370",
                    "term": "Neoplasms by Histologic Type"
                },
                {
                    "id": "D000009369",
                    "term": "Neoplasms"
                },
                {
                    "id": "D000009380",
                    "term": "Neoplasms, Nerve Tissue"
                },
                {
                    "id": "D000018326",
                    "term": "Nevi and Melanomas"
                },
                {
                    "id": "D000012878",
                    "term": "Skin Neoplasms"
                },
                {
                    "id": "D000009371",
                    "term": "Neoplasms by Site"
                },
                {
                    "id": "D000012871",
                    "term": "Skin Diseases"
                }
            ],
            "browseLeaves": [
                {
                    "id": "M11528",
                    "name": "Melanoma",
                    "asFound": "Melanoma",
                    "relevance": "HIGH"
                },
                {
                    "id": "M3212",
                    "name": "Melanoma, Cutaneous Malignant",
                    "relevance": "LOW"
                },
                {
                    "id": "M20495",
                    "name": "Neuroendocrine Tumors",
                    "relevance": "LOW"
                },
                {
                    "id": "M19845",
                    "name": "Neuroectodermal Tumors",
                    "relevance": "LOW"
                },
                {
                    "id": "M20388",
                    "name": "Neuroectodermal Tumors, Primitive",
                    "relevance": "LOW"
                },
                {
                    "id": "M12318",
                    "name": "Neoplasms, Germ Cell and Embryonal",
                    "relevance": "LOW"
                },
                {
                    "id": "M12315",
                    "name": "Neoplasms by Histologic Type",
                    "relevance": "LOW"
                },
                {
                    "id": "M12325",
                    "name": "Neoplasms, Nerve Tissue",
                    "relevance": "LOW"
                },
                {
                    "id": "M12448",
                    "name": "Nevus, Pigmented",
                    "relevance": "LOW"
                },
                {
                    "id": "M12446",
                    "name": "Nevus",
                    "relevance": "LOW"
                },
                {
                    "id": "M20470",
                    "name": "Nevi and Melanomas",
                    "relevance": "LOW"
                },
                {
                    "id": "M15681",
                    "name": "Skin Neoplasms",
                    "relevance": "LOW"
                },
                {
                    "id": "M15674",
                    "name": "Skin Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "T4091",
                    "name": "Neuroendocrine Tumor",
                    "relevance": "LOW"
                },
                {
                    "id": "T4092",
                    "name": "Neuroepithelioma",
                    "relevance": "LOW"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "BC04",
                    "name": "Neoplasms"
                },
                {
                    "abbrev": "BC17",
                    "name": "Skin and Connective Tissue Diseases"
                },
                {
                    "abbrev": "All",
                    "name": "All Conditions"
                },
                {
                    "abbrev": "Rare",
                    "name": "Rare Diseases"
                }
            ]
        },
        "interventionBrowseModule": {
            "meshes": [
                {
                    "id": "D000077204",
                    "term": "Temozolomide"
                },
                {
                    "id": "D000003606",
                    "term": "Dacarbazine"
                },
                {
                    "id": "C000560077",
                    "term": "Trametinib"
                },
                {
                    "id": "C000723373",
                    "term": "Naporafenib"
                }
            ],
            "ancestors": [
                {
                    "id": "D000018906",
                    "term": "Antineoplastic Agents, Alkylating"
                },
                {
                    "id": "D000000477",
                    "term": "Alkylating Agents"
                },
                {
                    "id": "D000045504",
                    "term": "Molecular Mechanisms of Pharmacological Action"
                },
                {
                    "id": "D000000970",
                    "term": "Antineoplastic Agents"
                },
                {
                    "id": "D000047428",
                    "term": "Protein Kinase Inhibitors"
                },
                {
                    "id": "D000004791",
                    "term": "Enzyme Inhibitors"
                }
            ],
            "browseLeaves": [
                {
                    "id": "M1692",
                    "name": "Temozolomide",
                    "asFound": "Cervical",
                    "relevance": "HIGH"
                },
                {
                    "id": "M218495",
                    "name": "Trametinib",
                    "asFound": "Surgery:",
                    "relevance": "HIGH"
                },
                {
                    "id": "M6809",
                    "name": "Dacarbazine",
                    "asFound": "Affect",
                    "relevance": "HIGH"
                },
                {
                    "id": "M352728",
                    "name": "Naporafenib",
                    "asFound": "Resin bonded bridge",
                    "relevance": "HIGH"
                },
                {
                    "id": "M20942",
                    "name": "Antineoplastic Agents, Alkylating",
                    "relevance": "LOW"
                },
                {
                    "id": "M3820",
                    "name": "Alkylating Agents",
                    "relevance": "LOW"
                },
                {
                    "id": "M25820",
                    "name": "Protein Kinase Inhibitors",
                    "relevance": "LOW"
                },
                {
                    "id": "M7951",
                    "name": "Enzyme Inhibitors",
                    "relevance": "LOW"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "ANeo",
                    "name": "Antineoplastic Agents"
                },
                {
                    "abbrev": "All",
                    "name": "All Drugs and Chemicals"
                }
            ]
        }
    },
    "hasResults": false
}